Cargando…

Therapeutic efficacy and safety of S-1-based combination therapy compare with S-1 monotherapy following gemcitabine failure in pancreatic cancer: a meta-analysis

S-1 monotherapy is widely used following gemcitabine failure in pancreatic cancer, especially in East Asia. We performed a meta-analysis to determine whether S-1-based combination therapy had better efficacy and safety compared with S-1 monotherapy. We searched Pubmed, Web of Science, ClinicalTrials...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Sinan, Zhang, Yuan, Zhou, Xiaohu, Zhou, Dongkai, Yang, Qifan, Ju, Bingjie, Zhao, Xinyi, Hu, Zhenhua, Xie, Haiyang, Zhou, Lin, Zheng, Shusen, Wang, Weilin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5105146/ https://www.ncbi.nlm.nih.gov/pubmed/27833144 http://dx.doi.org/10.1038/srep36944

Ejemplares similares

USPs in Pancreatic Ductal Adenocarcinoma: A Comprehensive Bioinformatic Analysis of Expression, Prognostic Significance, and Immune Infiltration
por: Wang, Yizhi, et al.
Publicado: (2022)

The Role of Microtubules in Pancreatic Cancer: Therapeutic Progress
por: Albahde, Mugahed Abdullah Hasan, et al.
Publicado: (2021)

High Expression of ITGA3 Promotes Proliferation and Cell Cycle Progression and Indicates Poor Prognosis in Intrahepatic Cholangiocarcinoma
por: Huang, Yu, et al.
Publicado: (2018)

Overexpression of β3 Chains of Laminin-332 is Associated With Clinicopathologic Features and Decreased Survival in Patients With Pancreatic Adenocarcinoma
por: Chen, Jun, et al.
Publicado: (2015)

Clinical significance of mitofusin-2 and its signaling pathways in hepatocellular carcinoma
por: Wu, Yingsheng, et al.
Publicado: (2016)

Pancreatoduodenectomy combined with portal-superior mesenteric vein resection and reconstruction with interposition grafts for cancer: a meta-analysis
por: Song, Wei, et al.
Publicado: (2017)

Expression and Clinical Significance of the Novel Long Noncoding RNA ZNF674-AS1 in Human Hepatocellular Carcinoma
por: Zhang, Lufei, et al.
Publicado: (2016)

A rare variation of celiac trunk and hepatic artery complicating pancreaticoduodenectomy: A case report and literature review
por: Ye, Zhou, et al.
Publicado: (2017)

Identification of chemoresistance‐related mRNAs based on gemcitabine‐resistant pancreatic cancer cell lines
por: Zhou, Jiarong, et al.
Publicado: (2019)

Integrative Analysis of ceRNA Network Reveals Functional lncRNAs in Intrahepatic Cholangiocarcinoma
por: Zhou, Dongkai, et al.
Publicado: (2019)

Pralatrexate mediates effective killing of gemcitabine-resistant pancreatic cancer: role of mTOR/4E-BP1 signal pathway
por: Weng, Wanwen, et al.
Publicado: (2022)

Real‐world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma
por: de Jong, Evelien J. M., et al.
Publicado: (2021)

Comparison of adjuvant gemcitabine plus S-1 with S-1 monotherapy for pancreatic ductal adenocarcinoma: Retrospective real-world data
por: Tang, Hui, et al.
Publicado: (2022)

Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-naïve advanced pancreatic ductal adenocarcinoma
por: Zhu, Zhou, et al.
Publicado: (2023)

A Meta-Analysis of Randomized Controlled Trials of Low-Volume Polyethylene Glycol plus Ascorbic Acid versus Standard-Volume Polyethylene Glycol Solution as Bowel Preparations for Colonoscopy
por: Xie, Qingsong, et al.
Publicado: (2014)

Ras-related associated with diabetes gene acts as a suppressor and inhibits Warburg effect in hepatocellular carcinoma
por: Yan, Yingcai, et al.
Publicado: (2016)

BCL6B expression in hepatocellular carcinoma and its efficacy in the inhibition of liver damage and fibrogenesis
por: Wang, Weilin, et al.
Publicado: (2015)

miR-448 targets Rab2B and is pivotal in the suppression of pancreatic cancer
por: Jin, Jing, et al.
Publicado: (2018)

The effectiveness of nab-paclitaxel plus gemcitabine and gemcitabine monotherapy in first-line metastatic pancreatic cancer treatment: A real-world evidence
por: Prejac, Juraj, et al.
Publicado: (2022)

Efficacy and Safety of Everolimus plus Somatostatin Analogues in Patients with Neuroendocrine Tumors
por: Ge, Wenhao, et al.
Publicado: (2018)

Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in Unresectable Pancreatic Cancer
por: Hino, Kaori, et al.
Publicado: (2022)

Pretreatment with Gemcitabine/5-Fluorouracil Enhances the Cytotoxicity of Trastuzumab to HER2-Negative Human Gallbladder Cancer Cells In Vitro and In Vivo
por: Wang, Wei, et al.
Publicado: (2019)

Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis
por: Li, Doudou, et al.
Publicado: (2015)

A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer(†)
por: Ueno, M., et al.
Publicado: (2016)

S-1 monotherapy versus S-1 combination therapy in gemcitabine-refractory advanced pancreatic cancer: A meta-analysis (PRISMA) of randomized control trials
por: Zhong, Sheng, et al.
Publicado: (2017)

MicroRNA‐761 is upregulated in hepatocellular carcinoma and regulates tumorigenesis by targeting Mitofusin‐2
por: Zhou, Xiaohu, et al.
Publicado: (2016)

Gemcitabine Monotherapy Associated with Posterior Reversible Encephalopathy Syndrome
por: Marrone, Luiz Carlos Porcello, et al.
Publicado: (2011)

COL6A1 promotes metastasis and predicts poor prognosis in patients with pancreatic cancer
por: Owusu-Ansah, Kwabena Gyabaah, et al.
Publicado: (2019)

The efficacy and safety of gemcitabine-based combination therapy vs. gemcitabine alone for the treatment of advanced pancreatic cancer: a systematic review and meta-analysis
por: Zhang, Zhaohuan, et al.
Publicado: (2022)

A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin
por: Zheng, Yi, et al.
Publicado: (2018)

Long non-coding RNA CASC15 is upregulated in hepatocellular carcinoma and facilitates hepatocarcinogenesis
por: He, Tianyu, et al.
Publicado: (2017)

Gemcitabine plus S-1 for metastatic pancreatic cancer
por: Zhu, Hong, et al.
Publicado: (2018)

Are ENT1/ENT1, NOTCH3, and miR-21 Reliable Prognostic Biomarkers in Patients with Resected Pancreatic Adenocarcinoma Treated with Adjuvant Gemcitabine Monotherapy?
por: Jiraskova, Lucie, et al.
Publicado: (2019)

First-line chemotherapy in very elderly patients with metastatic pancreatic cancer: Gemcitabine monotherapy vs combination chemotherapy
por: Han, Sung Yong, et al.
Publicado: (2020)

RRM1 predicts clinical outcome of high-and intermediate-risk non-muscle-invasive bladder cancer patients treated with intravesical gemcitabine monotherapy
por: Yang, Zhenxing, et al.
Publicado: (2019)

Number of Positive Lymph Nodes Is Superior to LNR and LODDS for Predicting the Prognosis of Pancreatic Neuroendocrine Neoplasms
por: Gao, Bingqiang, et al.
Publicado: (2021)

STAT1-mediated inhibition of FOXM1 enhances gemcitabine sensitivity in pancreatic cancer
por: Liu, Chao, et al.
Publicado: (2019)

A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer
por: Stathopoulos, G P, et al.
Publicado: (2006)

Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma
por: Zong, Yuan, et al.
Publicado: (2020)

Combination therapy versus gemcitabine monotherapy in the treatment of elderly pancreatic cancer: a meta-analysis of randomized controlled trials
por: Jin, Jiamin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6crpme8hcph05k7ippnhj7tfmi